Skip to main content
Livermore
Livermore
ZHEN

ArriVent BioPharma, Inc.

AVBP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001868279

No open-market purchases or sales by ArriVent BioPharma, Inc. insiders were filed in the last 90 days; 157 institutions reported holding it in 13F filings for Q2 2026, worth $1.60B in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.

Holders of 5% or more of AVBP

Holders whose latest Schedule 13D or 13G filing reports 5% or more of ArriVent BioPharma, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of AVBP
HolderLatest formStakeChangeFirst filedLatest filingFiling
Infinitum Asset Management, LLC13G/A9.90%4.12M shares0.00 ppfrom 9.90%May 15, 20253 filingsFeb 17, 2026SEC
Suvretta Capital Management, LLC13G/A9.90%3.41M shares–Aug 13, 20251 filingAug 13, 2025SEC
Hillhouse Investment Management, Ltd.13G/A9.50%3.93M shares–Feb 17, 20261 filingFeb 17, 2026SEC
OrbiMed Advisors LLC13D/A7.50%3.03M shares–Aug 13, 20251 filingAug 13, 2025SEC
FMR LLC13G/A6.80%3.02M shares−1.60 ppfrom 8.40%Nov 5, 20252 filingsMay 6, 2026SEC
BlackRock, Inc.13G5.60%2.32M shares+0.70 ppfrom 4.90%Oct 17, 20252 filingsJan 21, 2026SEC
HBM Healthcare Investments (Cayman) Ltd.13G5.40%2.20M sharesNewOct 15, 20251 filingOct 15, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

17 Schedule 13D and 13G filings on ArriVent BioPharma, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on AVBP
Filed (ET)FilerFormStakeChangeEvent dateFiling
May 6, 202611:00 AM ETFMR LLCand 1 other13G/A6.80%3.02M shares−1.60 ppfrom 8.40%Mar 31, 2026SEC
Mar 5, 20266:08 AM ETSofinnova Venture Partners IX, L.P.and 4 others13G/A4.10%1.70M shares–Below 5%Dec 31, 2025SEC
Feb 17, 20264:34 PM ETInfinitum Asset Management, LLCand 2 others13G/A9.90%4.12M shares0.00 ppfrom 9.90%Dec 31, 2025SEC
Feb 17, 20269:00 AM ETHillhouse Investment Management, Ltd.13G/A9.50%3.93M shares–Dec 31, 2025SEC
Jan 30, 20261:28 PM ETVanguard Group Inc13G/A4.52%1.87M shares−0.48 ppfrom 5.00%Below 5%Dec 31, 2025SEC
Jan 21, 202612:30 PM ETBlackRock, Inc.13G5.60%2.32M shares+0.70 ppfrom 4.90%Dec 31, 2025SEC
Nov 14, 20254:46 PM ETOctagon Capital Advisors LPand 4 others13G/A4.90%1.97M shares–Below 5%Sep 30, 2025SEC
Nov 5, 202511:26 AM ETFMR LLCand 1 other13G/A8.40%3.41M shares–Sep 30, 2025SEC
Oct 30, 20252:04 PM ETVanguard Group Inc13G5.00%2.03M sharesNewSep 30, 2025SEC
Oct 17, 20256:05 PM ETBlackRock, Inc.13G/A4.90%2.01M shares–Below 5%Sep 30, 2025SEC
Oct 15, 20254:07 PM ETHBM Healthcare Investments (Cayman) Ltd.13G5.40%2.20M sharesNewOct 8, 2025SEC
Aug 14, 20254:59 PM ETNovo Holdings A/S13G/A4.90%1.87M shares−0.30 ppfrom 5.20%Below 5%Jun 30, 2025SEC
Aug 13, 20257:43 PM ETOrbiMed Advisors LLCand 3 others13D/A7.50%3.03M shares–Aug 11, 2025SEC
Aug 13, 20257:29 PM ETSuvretta Capital Management, LLCand 2 others13G/A9.90%3.41M shares–Jun 30, 2025SEC
Aug 13, 20256:00 PM ETInfinitum Asset Management, LLCand 2 others13G9.90%3.42M shares+3.80 ppfrom 6.10%May 1, 2025SEC
May 15, 20254:36 PM ETInfinitum Asset Management, LLCand 2 others13G6.10%2.07M sharesNewMay 1, 2025SEC
Feb 14, 20259:00 PM ETNovo Holdings A/S13G5.20%1.75M sharesNewFeb 7, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell ArriVent BioPharma, Inc. shares.

No Form 144 notices for ArriVent BioPharma, Inc. are on file.